| Literature DB >> 29162563 |
Leili Ran1, Yuedan Chen1,2, Jessica Sher1, Elissa W P Wong1, Devan Murphy1, Jenny Q Zhang1, Dan Li1, Kemal Deniz3, Inna Sirota4, Zhen Cao1,2, Shangqian Wang1, Youxin Guan1, Shipra Shukla1, Katie Yang Li5, Alan Chramiec5,6, Yuanyuan Xie1, Deyou Zheng7,8,9, Richard P Koche5, Cristina R Antonescu10, Yu Chen11,2,12,13, Ping Chi11,2,12,13.
Abstract
The cellular context that integrates upstream signaling and downstream nuclear response dictates the oncogenic behavior and shapes treatment responses in distinct cancer types. Here, we uncover that in gastrointestinal stromal tumor (GIST), the forkhead family member FOXF1 directly controls the transcription of two master regulators, KIT and ETV1, both required for GIST precursor-interstitial cells of Cajal lineage specification and GIST tumorigenesis. Further, FOXF1 colocalizes with ETV1 at enhancers and functions as a pioneer factor that regulates the ETV1-dependent GIST lineage-specific transcriptome through modulation of the local chromatin context, including chromatin accessibility, enhancer maintenance, and ETV1 binding. Functionally, FOXF1 is required for human GIST cell growth in vitro and murine GIST tumor growth and maintenance in vivo The simultaneous control of the upstream signaling and nuclear response sets up a unique regulatory paradigm and highlights the critical role of FOXF1 in enforcing the GIST cellular context for highly lineage-restricted clinical behavior and treatment response.Significance: We uncover that FOXF1 defines the core-regulatory circuitry in GIST through both direct transcriptional regulation and pioneer factor function. The unique and simultaneous control of signaling and transcriptional circuitry by FOXF1 sets up an enforced transcriptional addiction to FOXF1 in GIST, which can be exploited diagnostically and therapeutically. Cancer Discov; 8(2); 234-51. ©2017 AACR.See related commentary by Lee and Duensing, p. 146This article is highlighted in the In This Issue feature, p. 127. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29162563 PMCID: PMC5809271 DOI: 10.1158/2159-8290.CD-17-0468
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397